Rockville, MD – As innovations in immunotherapies multiply, cancer programs and practices must overcome care coordination and communication challenges across the nation’s siloed healthcare system to integrate these advances into effective patient care. A new report from the Association of Cancer Care Centers (ACCC), Immuno-Oncology: Transforming the Delivery of Cancer Care in the Community, explores ACCC’s actions to reduce these barriers with education, peer-to-peer learning, and real-time solutions.
A recent ACCC survey of more than 200 cancer centers1 showed that 96 percent of respondents report that they are prescribing immunotherapies if appropriate for the patient’s treatment. Yet nearly 40 percent said that they are either “very uncomfortable” or “somewhat uncomfortable” with managing immune-related adverse events (irAEs) and side effects.
These findings underscore an urgent need for education, support, and resources on how to integrate emerging immunotherapies, new indications, and evolving knowledge about the toxicities related to these treatments into practice. Immuno-Oncology: Transforming the Delivery of Cancer Care in the Community offers insights, resources, education, and details real-world challenges and solutions identified through ACCC’s immuno-oncology initiative in 2017. Included is a summary of the year’s most significant immunotherapy research and clinical developments, as well as effective approaches for cancer programs and providers in management of irAEs, patient education, and coordination of care with specialists (such as dermatologists, endocrinologists, pulmonologists, radiologists) who may see patients treated with immunotherapies for cancer.
Immunotherapy is recognized as a paradigm shift in cancer care. Immuno-Oncology: Transforming the Delivery of Cancer Care in the Community provides important perspective on the ripple effect of this new paradigm on the patient’s treatment experience, on cancer care processes and the multidisciplinary team, and on other healthcare providers involved in the patient’s care.
"As the I-O clinical landscape and volume of information evolves, establishing effective education and strong lines of communication become even more important – for every member of the care delivery team,” said Advisory Committee Chair Lee S. Schwartzberg, MD, FACP, Chief, Division of Hematology Oncology and Professor of Medicine at the University of Tennessee; and Executive Director of The West Cancer Center in Memphis, Tennessee. “ACCC meets these critical needs with peer-driven, need-to-know resources that share effective practices and create opportunities for real-time, clinician-to-clinician conversations about care delivery for patients on immunotherapy for cancer.”
Immuno-Oncology: Transforming the Delivery of Cancer Care in the Community explores the latest ACCC I-O resources on clinical optimization, coverage and reimbursement, operational effective practices, and patient access. Included are actionable steps for integrating new therapies into practice, along with a comprehensive look at the latest information on managing immune-related adverse events.
In today’s healthcare landscape, immuno-oncology agents are center stage not only because of the new hope they bring for many patients with cancer, but also because these costly therapies are at the intersection of cost, value, and innovation in cancer treatment. Immuno-Oncology: Transforming the Delivery of Cancer Care in the Community looks at stakeholders’ critical policy, access, and value concerns and points to four priority areas for 2018:
Throughout 2018 and beyond, ACCC’s immuno-oncology initiative will lead efforts to improve communication, care coordination, and education for all healthcare professionals involved in the delivery of immunotherapy and the care of patients treated with immunotherapy for cancer.
Download Immuno-Oncology: Transforming the Delivery of Cancer Care in the Community at http://accc-iclio.org/publication.
1. Highlights from the ACCC 2017 Trending Now in Cancer Care survey. Association of Cancer Care Centers and Advisory Board Oncology Roundtable. January 2018. Available online at accc-cancer.org.
December 21, 2021
December 21, 2021
September 13, 2021
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
